Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

Connection

Co-Authors

This is a "connection" page, showing publications co-authored by Ralph R. Weichselbaum and Sean Pitroda.

 
Connection Strength
 
 
 
10.200
 
  1. Pitroda SP, Weichselbaum RR. Integrated molecular and clinical staging defines the spectrum of metastatic cancer. Nat Rev Clin Oncol. 2019 09; 16(9):581-588.
    View in: PubMed
    Score: 0.848
  2. Pitroda SP, Chmura SJ, Weichselbaum RR. Integration of radiotherapy and immunotherapy for treatment of oligometastases. Lancet Oncol. 2019 08; 20(8):e434-e442.
    View in: PubMed
    Score: 0.842
  3. Pitroda SP, Khodarev NN, Huang L, Uppal A, Wightman SC, Ganai S, Joseph N, Pitt J, Brown M, Forde M, Mangold K, Xue L, Weber C, Segal JP, Kadri S, Stack ME, Khan S, Paty P, Kaul K, Andrade J, White KP, Talamonti M, Posner MC, Hellman S, Weichselbaum RR. Author Correction: Integrated molecular subtyping defines a curable oligometastatic state in colorectal liver metastasis. Nat Commun. 2018 11 13; 9(1):4827.
    View in: PubMed
    Score: 0.802
  4. Pitroda SP, Khodarev NN, Huang L, Uppal A, Wightman SC, Ganai S, Joseph N, Pitt J, Brown M, Forde M, Mangold K, Xue L, Weber C, Segal JP, Kadri S, Stack ME, Khan S, Paty P, Kaul K, Andrade J, White KP, Talamonti M, Posner MC, Hellman S, Weichselbaum RR. Integrated molecular subtyping defines a curable oligometastatic state in colorectal liver metastasis. Nat Commun. 2018 05 04; 9(1):1793.
    View in: PubMed
    Score: 0.773
  5. Pitroda SP, Zhou T, Sweis RF, Filippo M, Labay E, Beckett MA, Mauceri HJ, Liang H, Darga TE, Perakis S, Khan SA, Sutton HG, Zhang W, Khodarev NN, Garcia JG, Weichselbaum RR. Tumor endothelial inflammation predicts clinical outcome in diverse human cancers. PLoS One. 2012; 7(10):e46104.
    View in: PubMed
    Score: 0.525
  6. Pitroda SP, Khodarev NN, Beckett MA, Kufe DW, Weichselbaum RR. MUC1-induced alterations in a lipid metabolic gene network predict response of human breast cancers to tamoxifen treatment. Proc Natl Acad Sci U S A. 2009 Apr 07; 106(14):5837-41.
    View in: PubMed
    Score: 0.410
  7. Pointer KB, Pitroda SP, Weichselbaum RR. Radiotherapy and immunotherapy: open questions and future strategies. Trends Cancer. 2022 Jan; 8(1):9-20.
    View in: PubMed
    Score: 0.246
  8. Gutiontov SI, Turchan WT, Spurr LF, Rouhani SJ, Chervin CS, Steinhardt G, Lager AM, Wanjari P, Malik R, Connell PP, Chmura SJ, Juloori A, Hoffman PC, Ferguson MK, Donington JS, Patel JD, Vokes EE, Weichselbaum RR, Bestvina CM, Segal JP, Pitroda SP. CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer. Sci Rep. 2021 10 08; 11(1):20059.
    View in: PubMed
    Score: 0.245
  9. Turchan WT, Pitroda SP, Weichselbaum RR. Treatment of Cancer with Radio-Immunotherapy: What We Currently Know and What the Future May Hold. Int J Mol Sci. 2021 Sep 03; 22(17).
    View in: PubMed
    Score: 0.244
  10. Gutiontov S, Pitroda S, Weichselbaum R. The Spectrum of Metastasis: An Opportunity for Cure? Semin Radiat Oncol. 2021 Jul; 31(3):174-179.
    View in: PubMed
    Score: 0.241
  11. Turchan WT, Pitroda SP, Weichselbaum RR. Radiotherapy and Immunotherapy Combinations in the Treatment of Patients with Metastatic Disease: Current Status and Future Focus. Clin Cancer Res. 2021 Jun 17.
    View in: PubMed
    Score: 0.240
  12. Yang K, Hou Y, Zhang Y, Liang H, Sharma A, Zheng W, Wang L, Torres R, Tatebe K, Chmura SJ, Pitroda SP, Gilbert JA, Fu YX, Weichselbaum RR. Suppression of local type I interferon by gut microbiota-derived butyrate impairs antitumor effects of ionizing radiation. J Exp Med. 2021 03 01; 218(3).
    View in: PubMed
    Score: 0.235
  13. Hou Y, Liang HL, Yu X, Liu Z, Cao X, Rao E, Huang X, Wang L, Li L, Bugno J, Fu Y, Chmura SJ, Wu W, Luo SZ, Zheng W, Arina A, Jutzy J, McCall AR, Vokes EE, Pitroda SP, Fu YX, Weichselbaum RR. Radiotherapy and immunotherapy converge on elimination of tumor-promoting erythroid progenitor cells through adaptive immunity. Sci Transl Med. 2021 02 24; 13(582).
    View in: PubMed
    Score: 0.235
  14. Gutiontov SI, Pitroda SP, Tran PT, Weichselbaum RR. (Oligo)metastasis as a Spectrum of Disease. Cancer Res. 2021 05 15; 81(10):2577-2583.
    View in: PubMed
    Score: 0.233
  15. Gutiontov SI, Pitroda SP, Weichselbaum RR. Oligometastasis: Past, Present, Future. Int J Radiat Oncol Biol Phys. 2020 11 01; 108(3):530-538.
    View in: PubMed
    Score: 0.230
  16. Gutiontov SI, Pitroda SP, Chmura SJ, Arina A, Weichselbaum RR. Cytoreduction and the Optimization Of Immune Checkpoint Inhibition with Radiation Therapy. Int J Radiat Oncol Biol Phys. 2020 09 01; 108(1):17-26.
    View in: PubMed
    Score: 0.227
  17. Foster CC, Pitroda SP, Weichselbaum RR. Definition, Biology, and History of Oligometastatic and Oligoprogressive Disease. Cancer J. 2020 Mar/Apr; 26(2):96-99.
    View in: PubMed
    Score: 0.219
  18. Arina A, Beckett M, Fernandez C, Zheng W, Pitroda S, Chmura SJ, Luke JJ, Forde M, Hou Y, Burnette B, Mauceri H, Lowy I, Sims T, Khodarev N, Fu YX, Weichselbaum RR. Tumor-reprogrammed resident T cells resist radiation to control tumors. Nat Commun. 2019 09 02; 10(1):3959.
    View in: PubMed
    Score: 0.212
  19. Foster CC, Pitroda SP, Weichselbaum RR. Beyond Palliation: The Rationale for Metastasis-Directed Therapy for Metastatic Non-Small Cell Lung Cancer. J Thorac Oncol. 2019 09; 14(9):1510-1512.
    View in: PubMed
    Score: 0.209
  20. Foster CC, Pitroda SP, Weichselbaum RR. Staging the Metastatic Spectrum Through Integration of Clinical and Molecular Features. J Clin Oncol. 2019 05 20; 37(15):1270-1276.
    View in: PubMed
    Score: 0.206
  21. Foster CC, Weichselbaum RR, Pitroda SP. Oligometastatic prostate cancer: Reality or figment of imagination? Cancer. 2019 02 01; 125(3):340-352.
    View in: PubMed
    Score: 0.201
  22. Pitroda SP, Stack ME, Liu GF, Song SS, Chen L, Liang H, Parekh AD, Huang X, Roach P, Posner MC, Weichselbaum RR, Khodarev NN. JAK2 Inhibitor SAR302503 Abrogates PD-L1 Expression and Targets Therapy-Resistant Non-small Cell Lung Cancers. . 2018 04; 17(4):732-739.
    View in: PubMed
    Score: 0.191
  23. Pitroda SP, Bao R, Andrade J, Weichselbaum RR, Connell PP. Low Recombination Proficiency Score (RPS) Predicts Heightened Sensitivity to DNA-Damaging Chemotherapy in Breast Cancer. Clin Cancer Res. 2017 Aug 01; 23(15):4493-4500.
    View in: PubMed
    Score: 0.179
  24. Meng Y, Mauceri HJ, Khodarev NN, Darga TE, Pitroda SP, Beckett MA, Kufe DW, Weichselbaum RR. Ad.Egr-TNF and Local Ionizing Radiation Suppress Metastases by Interferon-ß-Dependent Activation of Antigen-specific CD8+ T Cells. Mol Ther. 2010 May; 18(5):912-920.
    View in: PubMed
    Score: 0.175
  25. Skowron KB, Pitroda SP, Namm JP, Balogun O, Beckett MA, Zenner ML, Fayanju O, Huang X, Fernandez C, Zheng W, Qiao G, Chin R, Kron SJ, Khodarev NN, Posner MC, Steinberg GD, Weichselbaum RR. Basal Tumor Cell Isolation and Patient-Derived Xenograft Engraftment Identify High-Risk Clinical Bladder Cancers. Sci Rep. 2016 10 24; 6:35854.
    View in: PubMed
    Score: 0.174
  26. Khodarev NN, Pitroda SP, Weichselbaum RR. microRNAs and oligometastasis. Aging (Albany NY). 2015 Mar; 7(3):146-7.
    View in: PubMed
    Score: 0.155
  27. Uppal A, Wightman SC, Mallon S, Oshima G, Pitroda SP, Zhang Q, Huang X, Darga TE, Huang L, Andrade J, Liu H, Ferguson MK, Greene GL, Posner MC, Hellman S, Khodarev NN, Weichselbaum RR. 14q32-encoded microRNAs mediate an oligometastatic phenotype. Oncotarget. 2015 Feb 28; 6(6):3540-52.
    View in: PubMed
    Score: 0.155
  28. Pitroda SP, Pashtan IM, Logan HL, Budke B, Darga TE, Weichselbaum RR, Connell PP. DNA repair pathway gene expression score correlates with repair proficiency and tumor sensitivity to chemotherapy. Sci Transl Med. 2014 Mar 26; 6(229):229ra42.
    View in: PubMed
    Score: 0.145
  29. MacDermed DM, Khodarev NN, Pitroda SP, Edwards DC, Pelizzari CA, Huang L, Kufe DW, Weichselbaum RR. MUC1-associated proliferation signature predicts outcomes in lung adenocarcinoma patients. BMC Med Genomics. 2010 May 06; 3:16.
    View in: PubMed
    Score: 0.111
  30. Meng Y, Mauceri HJ, Khodarev NN, Darga TE, Pitroda SP, Beckett MA, Kufe DW, Weichselbaum RR. Ad.Egr-TNF and local ionizing radiation suppress metastases by interferon-beta-dependent activation of antigen-specific CD8+ T cells. Mol Ther. 2010 May; 18(5):912-20.
    View in: PubMed
    Score: 0.110
  31. Pitroda SP, Wakim BT, Sood RF, Beveridge MG, Beckett MA, MacDermed DM, Weichselbaum RR, Khodarev NN. STAT1-dependent expression of energy metabolic pathways links tumour growth and radioresistance to the Warburg effect. BMC Med. 2009 Nov 05; 7:68.
    View in: PubMed
    Score: 0.107
  32. Khodarev NN, Roach P, Pitroda SP, Golden DW, Bhayani M, Shao MY, Darga TE, Beveridge MG, Sood RF, Sutton HG, Beckett MA, Mauceri HJ, Posner MC, Weichselbaum RR. STAT1 pathway mediates amplification of metastatic potential and resistance to therapy. PLoS One. 2009 Jun 08; 4(6):e5821.
    View in: PubMed
    Score: 0.104
  33. Khodarev NN, Pitroda SP, Beckett MA, MacDermed DM, Huang L, Kufe DW, Weichselbaum RR. MUC1-induced transcriptional programs associated with tumorigenesis predict outcome in breast and lung cancer. Cancer Res. 2009 Apr 01; 69(7):2833-7.
    View in: PubMed
    Score: 0.103
  34. Mauceri HJ, Beckett MA, Liang H, Sutton HG, Pitroda S, Galka E, Efimova E, Darga T, Khodarev NN, King CR, Posner MC, Hellman S, Kufe DW, Weichselbaum RR. Translational strategies exploiting TNF-alpha that sensitize tumors to radiation therapy. Cancer Gene Ther. 2009 Apr; 16(4):373-81.
    View in: PubMed
    Score: 0.100
  35. Dhiman A, Vining CC, Witmer HDD, Sood D, Shergill A, Kindler H, Roggin KK, Posner MC, Ahmed OS, Liauw S, Pitroda S, Liao CY, Karrison T, Weichselbaum R, Polite B, Eng OS, Catenacci DVT, Turaga KK. Phase II Prospective, Open-Label Randomized Controlled Trial Comparing Standard of Care Chemotherapy With and Without Sequential Cytoreductive Interventions for Patients with Oligometastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor Deoxyribose Nucleic Acid (ctDNA) Levels. Ann Surg Oncol. 2022 Jan 05.
    View in: PubMed
    Score: 0.062
  36. Pointer KB, Katipally RR, Bestvina CM, Juloori A, Partouche J, Patel JD, Pitroda SP, Vokes EE, Weichselbaum RR, Chmura SJ. Evaluation of Initial Metastatic Tumor Location and Radiation Response to Determine Outcomes in Patients Who Received Combination Stereotactic Body Radiotherapy and Immunotherapy for NSCLC. Int J Radiat Oncol Biol Phys. 2021 Nov 01; 111(3S):e449.
    View in: PubMed
    Score: 0.062
  37. Bestvina CM, Pointer KB, Karrison T, Al-Hallaq H, Hoffman PC, Jelinek MJ, Juloori A, Melotek JM, Murgu S, Partouche J, Vokes EE, Weichselbaum RR, Pitroda SP, Patel JD, Chmura SJ. A Phase 1 Trial of Concurrent or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients With Stage IV NSCLC Study. J Thorac Oncol. 2022 Jan; 17(1):130-140.
    View in: PubMed
    Score: 0.061
  38. Foster CC, Fleming GF, Karrison TG, Liao CY, Desai AV, Moroney JW, Ratain MJ, Nanda R, Polite BN, Hahn OM, O'Donnell PH, Vokes EE, Kindler HL, Hseu R, Janisch LA, Dai J, Hoffman MD, Weichselbaum RR, Pitroda SP, Chmura SJ, Luke JJ. Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors. Clin Cancer Res. 2021 10 15; 27(20):5510-5518.
    View in: PubMed
    Score: 0.060
  39. Luke JJ, Onderdonk BE, Bhave SR, Karrison T, Lemons JM, Chang P, Zha Y, Carll T, Krausz T, Huang L, Martinez C, Janisch LA, Hseu RD, Moroney JW, Patel JD, Khodarev NN, Salama JK, Ott PA, Fleming GF, Gajewski TF, Weichselbaum RR, Pitroda SP, Chmura SJ. Improved Survival Associated with Local Tumor Response Following Multisite Radiotherapy and Pembrolizumab: Secondary Analysis of a Phase I Trial. Clin Cancer Res. 2020 12 15; 26(24):6437-6444.
    View in: PubMed
    Score: 0.057
  40. Oshima G, Poli EC, Bolt MJ, Chlenski A, Forde M, Jutzy JMS, Biyani N, Posner MC, Pitroda SP, Weichselbaum RR, Khodarev NN. DNA Methylation Controls Metastasis-Suppressive 14q32-Encoded miRNAs. Cancer Res. 2019 02 01; 79(3):650-662.
    View in: PubMed
    Score: 0.050
  41. Luke JJ, Lemons JM, Karrison TG, Pitroda SP, Melotek JM, Zha Y, Al-Hallaq HA, Arina A, Khodarev NN, Janisch L, Chang P, Patel JD, Fleming GF, Moroney J, Sharma MR, White JR, Ratain MJ, Gajewski TF, Weichselbaum RR, Chmura SJ. Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors. J Clin Oncol. 2018 06 01; 36(16):1611-1618.
    View in: PubMed
    Score: 0.048
  42. Oshima G, Stack ME, Wightman SC, Bryan D, Poli E, Xue L, Skowron KB, Uppal A, Pitroda SP, Huang X, Posner MC, Hellman S, Weichselbaum RR, Khodarev NN. Advanced Animal Model of Colorectal Metastasis in Liver: Imaging Techniques and Properties of Metastatic Clones. J Vis Exp. 2016 11 30; (117).
    View in: PubMed
    Score: 0.044
  43. Wong AC, Watson SP, Pitroda SP, Son CH, Das LC, Stack ME, Uppal A, Oshima G, Khodarev NN, Salama JK, Weichselbaum RR, Chmura SJ. Clinical and molecular markers of long-term survival after oligometastasis-directed stereotactic body radiotherapy (SBRT). Cancer. 2016 07 15; 122(14):2242-50.
    View in: PubMed
    Score: 0.042
  44. Ranoa DR, Parekh AD, Pitroda SP, Huang X, Darga T, Wong AC, Huang L, Andrade J, Staley JP, Satoh T, Akira S, Weichselbaum RR, Khodarev NN. Cancer therapies activate RIG-I-like receptor pathway through endogenous non-coding RNAs. Oncotarget. 2016 May 03; 7(18):26496-515.
    View in: PubMed
    Score: 0.042
  45. Oshima G, Wightman SC, Uppal A, Stack ME, Pitroda SP, Oskvarek JJ, Huang X, Posner MC, Hellman S, Weichselbaum RR, Khodarev NN. Imaging of tumor clones with differential liver colonization. Sci Rep. 2015 Jun 22; 5:10946.
    View in: PubMed
    Score: 0.040
  46. Wightman SC, Uppal A, Pitroda SP, Ganai S, Burnette B, Stack M, Oshima G, Khan S, Huang X, Posner MC, Weichselbaum RR, Khodarev NN. Oncogenic CXCL10 signalling drives metastasis development and poor clinical outcome. Br J Cancer. 2015 Jul 14; 113(2):327-35.
    View in: PubMed
    Score: 0.039
  47. Takahashi H, Jin C, Rajabi H, Pitroda S, Alam M, Ahmad R, Raina D, Hasegawa M, Suzuki Y, Tagde A, Bronson RT, Weichselbaum R, Kufe D. MUC1-C activates the TAK1 inflammatory pathway in colon cancer. Oncogene. 2015 Oct 01; 34(40):5187-97.
    View in: PubMed
    Score: 0.039
  48. Widau RC, Parekh AD, Ranck MC, Golden DW, Kumar KA, Sood RF, Pitroda SP, Liao Z, Huang X, Darga TE, Xu D, Huang L, Andrade J, Roizman B, Weichselbaum RR, Khodarev NN. RIG-I-like receptor LGP2 protects tumor cells from ionizing radiation. Proc Natl Acad Sci U S A. 2014 Jan 28; 111(4):E484-91.
    View in: PubMed
    Score: 0.036
  49. Jin C, Rajabi H, Pitroda S, Li A, Kharbanda A, Weichselbaum R, Kufe D. Cooperative interaction between the MUC1-C oncoprotein and the Rab31 GTPase in estrogen receptor-positive breast cancer cells. PLoS One. 2012; 7(7):e39432.
    View in: PubMed
    Score: 0.032
  50. Khodarev N, Ahmad R, Rajabi H, Pitroda S, Kufe T, McClary C, Joshi MD, MacDermed D, Weichselbaum R, Kufe D. Cooperativity of the MUC1 oncoprotein and STAT1 pathway in poor prognosis human breast cancer. Oncogene. 2010 Feb 11; 29(6):920-9.
    View in: PubMed
    Score: 0.027
  51. Efimova EV, Liang H, Pitroda SP, Labay E, Darga TE, Levina V, Lokshin A, Roizman B, Weichselbaum RR, Khodarev NN. Radioresistance of Stat1 over-expressing tumour cells is associated with suppressed apoptotic response to cytotoxic agents and increased IL6-IL8 signalling. Int J Radiat Biol. 2009 May; 85(5):421-31.
    View in: PubMed
    Score: 0.026
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.